The Food and Drug Administration (FDA) has approved the antibiotic rifaximin (Xifaxan™, Salix) 200 mg to treat travelers’ diarrhea in patients 12 years of age and older. In clinical trials, the drug helped to shorten the duration of diarrhea for the most common cause of this disease, namely, noninvasive strains of Escherichia coli.
Rifaximin should not be used for diarrhea that is complicated by fever or blood in the stool or for diarrhea caused by pathogens other than E. coli. It should be discontinued if diarrhea symptoms worsen or last more than 24 to 48 hours. canadian cialis
The product is expected to be available in August 2004.